Incidence of Sunitinib induced thyroid dysfunction in renal cell carcinoma: a pilot retrospective audit

Abstract

Primary hypothyroidism is a common adverse effect of TKI therapy. The incidence of primary hypothyroidism in this cohort was 20% and is similar to hypothyroidism rates in published data from Sunitinib studies (14-46%). There appeared to be a significant delay between the diagnosis of overt primary hypothyroidism and the start of LT4 therapy. Regular pre-cycle TFT checks and close liaison with Endocrinology will help reduce morbidity from delayed diagnosis and treatment of hypothyroidism. 10% 3%